A REVIEW OF LIBMELDY

The tablet formulation of zanubrutinib (Brukinsa; BeOne) has become authorised for all five indications across quite a few hematological cancers.The modified stem cells provide the body with myeloid (immune) cells that deliver the ARSA enzyme, which will help break down the dangerous Establish-up of sulfatides and should quit the development of MLD